Comparative Pharmacology
Head-to-head clinical analysis: ANASTROZOLE versus CYTADREN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANASTROZOLE versus CYTADREN.
ANASTROZOLE vs CYTADREN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anastrozole is a selective non-steroidal aromatase inhibitor. It inhibits the conversion of androgens to estrogens in peripheral tissues, thereby reducing circulating estradiol levels. It has no intrinsic progestogenic, androgenic, or estrogenic activity.
Aminoglutethimide inhibits the conversion of cholesterol to pregnenolone, thereby blocking adrenal steroidogenesis. It also inhibits aromatase, reducing estrogen synthesis.
1 mg orally once daily
200 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: ~46 hours (range 30–60 hours). Clinically, steady-state reached after ~10 days; once-daily dosing maintains therapeutic concentrations.
Clinical Note
moderateAnastrozole + Digoxin
"Anastrozole may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAnastrozole + Digitoxin
"Anastrozole may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAnastrozole + Deslanoside
"Anastrozole may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAnastrozole + Acetyldigitoxin
"Anastrozole may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 3–4 hours in adults with normal renal function; prolonged to 8–12 hours in end-stage renal disease.
Primarily hepatic metabolism (85%): N-dealkylation, hydroxylation, and glucuronidation. Renal excretion of metabolites: ~10% unchanged drug in urine. Fecal elimination: ~10% as metabolites.
Renal: ~60% as unchanged drug; biliary/fecal: ~25% as metabolites; minor via respiration.
Category D/X
Category C
Aromatase Inhibitor
Aromatase Inhibitor